SCHEMBL8764825

SCHEMBL8764825

O=C1C=CC(=O)N1COCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 6/20 0.59
GSK3A P49840 4/20 0.59
GSK3B P49841 4/20 0.59
TSHR P16473 1/20 0.54
FAAH O00519 3/20 0.50
ALDH1A1 P00352 4/20 0.45
MAPK1 P28482 1/20 0.44
F2 P00734 1/20 0.42
PLG P00747 1/20 0.42
ELANE P08246 1/20 0.42
CTSG P08311 1/20 0.42
CMA1 P23946 1/20 0.42
CTRC Q99895 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CYP1A2 P05177 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40
BLM P54132 1/20 0.40
WRN Q14191 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5828559 0.79 ALDH1A1 (0.49) MGLLGSK3AGSK3BTSHRALDH1A1
SCHEMBL12769594 0.77 ELANE (0.53) MGLLGSK3AGSK3BTSHRFAAH
SCHEMBL8062425 0.75 GSK3A (0.63) GSK3AGSK3BTSHRALDH1A1MAPK1
SCHEMBL145760 0.75 MGLL (0.56) MGLLGSK3AGSK3BFAAHALDH1A1
SCHEMBL11062218 0.74 ALDH1A1 (0.58) MGLLGSK3AGSK3BTSHRFAAH
SCHEMBL25435490 0.74 MGLL (1.00) MGLLGSK3AGSK3BFAAHALDH1A1
Benzoquinone SCHEMBL8469988 0.74 TSHR (0.71) TSHRALDH1A1MAPK1MAOAMAOB
SCHEMBL207740 0.74 MGLL (1.00) MGLLGSK3AGSK3BFAAHALDH1A1
SCHEMBL5225296 0.73 MGLL (0.50) MGLLGSK3AGSK3BTSHRFAAH
SCHEMBL14686924 0.73 ALDH1A1 (0.44) TSHRALDH1A1MAPK1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-01-15 US disclosed
EP-4540255-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 EP disclosed
CN-119677749-A Azaquinazoline pan KRAS inhibitors 米拉蒂治疗股份有限公司 2025-03-21 CN disclosed
WO-2023244615-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 WO disclosed
EP-0601974-B1 Positive photoresist with better properties OCG MICROELECTRONIC MATERIALS (US) 1997-05-28 EP disclosed
US-5558978-A Photoresist compositions containing copolymers having acid-labile groups and recurring units derived from either N-(hydroxymethyl)maleimide or N-(acetoxymethyl)maleimide or both OCG MICROELECTRONIC MATERIALS, INC. (US) 1996-09-24 US disclosed
EP-0659781-A2 Copolymers of maleimide, for photoresists OCG Microelectronic Materials Inc. (US) 1995-06-28 EP disclosed
US-5397680-A Light sensitive elements with maleimide monomers and styrene derivatives polymers CIBA-GEIGY AG (CH) 1995-03-14 US disclosed
US-5369200-A Positive photoresist having improved processing properties CIBA-GEIGY AG (CH) 1994-11-29 US disclosed
EP-0601974-A1 Positive photoresist with better properties OCG Microelectronic Materials Inc. (US) 1994-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS MGLL 4310/4885GSK3A 1615/4885GSK3B 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.